A phenotypic risk score for predicting mortality in sickle cell disease.


Journal

British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544

Informations de publication

Date de publication:
03 2021
Historique:
received: 21 10 2020
accepted: 30 12 2020
pubmed: 29 1 2021
medline: 10 8 2021
entrez: 28 1 2021
Statut: ppublish

Résumé

Risk assessment for patients with sickle cell disease (SCD) remains challenging as it depends on an individual physician's experience and ability to integrate a variety of test results. We aimed to provide a new risk score that combines clinical, laboratory, and imaging data. In a prospective cohort of 600 adult patients with SCD, we assessed the relationship of 70 baseline covariates to all-cause mortality. Random survival forest and regularised Cox regression machine learning (ML) methods were used to select top predictors. Multivariable models and a risk score were developed and internally validated. Over a median follow-up of 4·3 years, 131 deaths were recorded. Multivariable models were developed using nine independent predictors of mortality: tricuspid regurgitant velocity, estimated right atrial pressure, mitral E velocity, left ventricular septal thickness, body mass index, blood urea nitrogen, alkaline phosphatase, heart rate and age. Our prognostic risk score had superior performance with a bias-corrected C-statistic of 0·763. Our model stratified patients into four groups with significantly different 4-year mortality rates (3%, 11%, 35% and 75% respectively). Using readily available variables from patients with SCD, we applied ML techniques to develop and validate a mortality risk scoring method that reflects the summation of cardiopulmonary, renal and liver end-organ damage. Trial Registration: ClinicalTrials.gov Identifier: NCT#00011648.

Identifiants

pubmed: 33506990
doi: 10.1111/bjh.17342
pmc: PMC9123430
mid: NIHMS1804164
doi:

Substances chimiques

Alkaline Phosphatase EC 3.1.3.1

Banques de données

ClinicalTrials.gov
['NCT00011648']

Types de publication

Journal Article Observational Study Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

932-941

Subventions

Organisme : NHLBI NIH HHS
Pays : United States
Organisme : NIH
Organisme : )
Organisme : Intramural Research Program
Organisme : DHHS
Organisme : Intramural NIH HHS
ID : ZIA HL006233
Pays : United States

Informations de copyright

Published 2021. This article is a U.S. Government work and is in the public domain in the USA.

Références

N Engl J Med. 2004 Feb 26;350(9):886-95
pubmed: 14985486
Br J Haematol. 2011 Aug;154(4):512-20
pubmed: 21689089
Circ Res. 2017 Oct 13;121(9):1092-1101
pubmed: 28794054
Haematologica. 2017 Apr;102(4):626-636
pubmed: 28104703
N Engl J Med. 2015 Jul 2;373(1):35-47
pubmed: 26132940
Clin Lab Haematol. 2005 Dec;27(6):384-90
pubmed: 16307540
Clin Liver Dis. 2019 May;23(2):177-189
pubmed: 30947870
Blood Cells Mol Dis. 2018 Sep;72:1-9
pubmed: 29778312
J Am Coll Cardiol. 2007 Jan 30;49(4):472-9
pubmed: 17258093
Eur Heart J. 2017 Jun 14;38(23):1805-1814
pubmed: 27436868
Circulation. 2014 Jun 24;129(25 Suppl 2):S49-73
pubmed: 24222018
Eur Heart J. 2016 Apr 7;37(14):1158-1167
pubmed: 26516176
Annu Rev Genomics Hum Genet. 2018 Aug 31;19:113-147
pubmed: 29641911
Clin J Am Soc Nephrol. 2016 Feb 5;11(2):207-15
pubmed: 26672090
Blood Cells Mol Dis. 2019 Feb;74:25-29
pubmed: 30391047
PLoS One. 2015 Aug 13;10(8):e0135472
pubmed: 26270484
Ann Intern Med. 2015 Jan 6;162(1):W1-73
pubmed: 25560730
PLoS One. 2016 Oct 20;11(10):e0164743
pubmed: 27764159
PLoS One. 2014 Jul 02;9(7):e99489
pubmed: 24988120
Br J Haematol. 2019 Sep;186(6):900-907
pubmed: 31168785
Trends Cardiovasc Med. 2021 Apr;31(3):187-193
pubmed: 32139143
Stat Med. 2019 Oct 15;38(23):4574-4582
pubmed: 31304613
PLoS One. 2017 Apr 4;12(4):e0174944
pubmed: 28376093
Blood. 2007 Oct 1;110(7):2727-35
pubmed: 17600133
Stat Med. 1999 Sep 15-30;18(17-18):2529-45
pubmed: 10474158
Am J Hematol. 2014 May;89(5):530-5
pubmed: 24478166
J R Stat Soc Series B Stat Methodol. 2012 Mar;74(2):245-266
pubmed: 25506256
J Clin Med Res. 2017 Oct;9(10):889-890
pubmed: 28912927

Auteurs

Vandana Sachdev (V)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Xin Tian (X)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Yuan Gu (Y)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

James Nichols (J)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Stanislav Sidenko (S)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Wen Li (W)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Andrea Beri (A)

Clinical Center, National Institutes of Health, Bethesda, MD, USA.

W Austin Layne (WA)

Clinical Center, National Institutes of Health, Bethesda, MD, USA.

Darlene Allen (D)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Colin O Wu (CO)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Swee Lay Thein (SL)

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH